250mg Gefticip Gefitinib Tablets

Gefticip 250mg Tablets contains Gefitinib which belongs to the group of medicines called Antineoplastics. It is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have activating mutation of the EGFR-TK.

It is generally characterized by symptoms such as chest pain or discomfort, persistent cough, trouble breathing, wheezing, tiredness and difficulty while swallowing which may be diagnosed as any of its type as adenocarcinoma (cancer involving the outer part of the lung), squamous cell carcinoma (cancer occurring in the centre part of the lungs), and large cell carcinoma (cancer that can occur in any part of the lung).